NDUFS1 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NDUFS1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFS1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFS1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NDUFS1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">29 edges</a></td>
</tr>
</table>
NDUFS1 is the largest catalytic core subunit of mitochondrial Complex I (NADH:ubiquinone oxidoreductase), the major entry point for electrons from NADH into the respiratory chain. In [neurons](/entities/neurons), Complex I sits at the intersection of ATP generation, redox balance, and mitochondrial stress signaling, so NDUFS1 dysfunction can amplify selective vulnerability in high-demand regions such as substantia nigra and cortical association networks. Pathogenic variants in [NDUFS1](/genes/ndufs1) are a recognized cause of severe mitochondrial disease phenotypes, often presenting with early encephalopathy, lactic acidosis, and Leigh-spectrum neurodegeneration.
Protein Architecture And Biochemistry
...NDUFS1 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NDUFS1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NDUFS1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NDUFS1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NDUFS1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">29 edges</a></td>
</tr>
</table>
NDUFS1 is the largest catalytic core subunit of mitochondrial Complex I (NADH:ubiquinone oxidoreductase), the major entry point for electrons from NADH into the respiratory chain. In [neurons](/entities/neurons), Complex I sits at the intersection of ATP generation, redox balance, and mitochondrial stress signaling, so NDUFS1 dysfunction can amplify selective vulnerability in high-demand regions such as substantia nigra and cortical association networks. Pathogenic variants in [NDUFS1](/genes/ndufs1) are a recognized cause of severe mitochondrial disease phenotypes, often presenting with early encephalopathy, lactic acidosis, and Leigh-spectrum neurodegeneration.
Protein Architecture And Biochemistry
NDUFS1 belongs to the matrix arm of Complex I and contributes to the proximal electron-transfer module that accepts electrons from NADH and transmits them through iron-sulfur centers toward ubiquinone reduction.[@fiedorczuk2018][@koopman2012] Structural studies of mammalian Complex I indicate that NDUFS1 helps stabilize the catalytic scaffold connecting N-module redox chemistry to long-range conformational coupling across the membrane arm.[@fiedorczuk2018][@kampjut2020]
Functionally, this means NDUFS1 is not just a passive structural element. It modulates the efficiency and fidelity of electron transfer and can influence how much electron leak is diverted into superoxide production under stress states.[@koopman2012][@vinogradov2008] In the CNS, where sustained oxidative phosphorylation is required for synaptic transmission and axonal transport, even modest destabilization of this step can trigger energetic failure and secondary inflammatory signaling.[@schapira2012][@johri2012]
Role In Neurodegeneration-Relevant Pathways
NDUFS1-linked dysfunction converges on several pathways that recur across neurodegenerative disorders:
Bioenergetic insufficiency: Reduced Complex I flux lowers ATP reserve, compromising proteostasis, vesicle cycling, and axonal trafficking.[@koopman2012][@schapira2012]
Oxidative stress escalation: Impaired electron flow increases [ROS](/entities/reactive-oxygen-species) burden and damages lipids, mtDNA, and respiratory proteins, creating a feed-forward decline.[@koopman2012][@vinogradov2008]
Mitophagy pressure: Damaged mitochondria must be cleared via [PINK1](/genes/pink1)-[PRKN](/genes/prkn) quality-control programs; when compensation fails, dysfunctional mitochondria accumulate.[@pickrell2015][@exner2012]
Neuroinflammatory coupling: Energetic stress and mtDAMP release potentiate microglial activation and chronic inflammatory tone in vulnerable circuits.[@schapira2012][@johri2012]These mechanisms are relevant to [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and atypical parkinsonian syndromes where mitochondrial stress appears upstream of overt neuronal loss in at least a subset of patients.[@koopman2012][@schapira2012][@vinogradov2008]
Human Genetics And Clinical Phenotypes
Biallelic NDUFS1 pathogenic variants are classically associated with infantile/early-childhood mitochondrial disease, often including developmental regression, seizures, hypotonia, and Leigh-like basal ganglia/brainstem lesions.[@smeitink2001][@lake2016] Phenotypic severity varies by residual complex assembly and enzyme activity, but severe presentations typically reflect major impairment of respiratory chain throughput.[@smeitink2001][@lake2016]
Although monogenic NDUFS1 disease is rare compared with common sporadic neurodegeneration, it provides an instructive human model of how chronic Complex I failure can drive network-level CNS degeneration.[@schapira2012][@smeitink2001] This translational bridge is relevant when evaluating mitochondrial-support interventions in broader neurodegenerative cohorts.
Biomarkers And Translational Readouts
For NDUFS1-related biology, useful translational readouts include:
- Respiratory chain enzyme activity (muscle/fibroblast) with Complex I emphasis[@smeitink2001][@lake2016]
- Lactate and metabolic stress markers during decompensation episodes[@smeitink2001]
- MRI signatures of mitochondrial encephalopathy patterns[@lake2016]
- Exploratory biofluid markers of mitochondrial injury and oxidative burden in adult neurodegeneration cohorts[@schapira2012][@johri2012]
In treatment-development settings, combining molecular markers (complex activity, redox metrics) with clinical outcomes is important because compensatory pathways can mask early disease kinetics.[@koopman2012][@vinogradov2008]
Therapeutic Strategy Landscape
No approved therapy directly restores NDUFS1 function in humans. Current management remains largely supportive and syndrome-oriented. Mechanistically, strategies under investigation across Complex I disorders and broader neurodegeneration include:
- Electron transport support with [coenzyme Q10](/therapeutics/coenzyme-q10-neurodegeneration) and related redox carriers[@beal2005]
- NAD/NADH axis optimization via [NAD+ precursors](/therapeutics/nad-precursors-neurodegeneration) to improve metabolic flexibility[@lautrup2019]
- Mitochondrial resilience programs (exercise, redox control, anti-inflammatory co-therapies) under [mitochondrial neuroprotection](/therapeutics/mitochondrial-neuroprotection)[@schapira2012][@beal2005]
For severe inherited Complex I deficiency, future directions include genotype-specific molecular correction, but major delivery and safety hurdles remain for CNS-targeted therapy.[@lake2016][@kampjut2020]
Research Priorities
Key open questions for NDUFS1-focused work in neurodegeneration:
- Which partial-loss NDUFS1 states are sufficient to shift neurons into irreversible stress trajectories?
- How should NDUFS1 dysfunction be stratified relative to other Complex I subunit defects in precision trial design?
- What biomarker combinations best capture short-term response versus long-term neuroprotection?
Addressing these questions could improve mechanistic patient selection and reduce false-negative outcomes in mitochondrial-targeted interventions.[@schapira2012][@vinogradov2008][@beal2005]
See Also
- [NDUFS1](/genes/ndufs1)
- [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Coenzyme Q10 and Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration)
- [NAD+ Precursors for Neurodegeneration](/therapeutics/nad-precursors-neurodegeneration)
External Links
- [UniProt: ndufs1](https://www.uniprot.org/)
- [PubMed: ndufs1](https://pubmed.ncbi.nlm.nih.gov/?term=ndufs1+neurodegeneration)
References
[Fiedorczuk K, Sazanov LA, Mammalian mitochondrial complex I structure and disease-causing mutations (2018)](https://doi.org/10.1016/j.tibs.2018.12.008)
[Koopman WJH, Willems PHGM, Smeitink JAM, Monogenic mitochondrial disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22710213/)
[Schapira AHV, Mitochondrial diseases (2012)](https://doi.org/10.1016/S1474-4422(12)
[Smeitink JAM, van den Heuvel LP, DiMauro S, The genetics and pathology of oxidative phosphorylation (2001)](https://pubmed.ncbi.nlm.nih.gov/16716639/)
[Lake NJ, Compton AG, Rahman S, Thorburn DR, Leigh syndrome: one disorder, more than 75 monogenic causes (2016)](https://doi.org/10.1016/S1474-4422(15)
[Kampjut D, Sazanov LA, Structure of respiratory complex I (2020)](https://doi.org/10.1146/annurev-biochem-011520-104240)
[Vinogradov AD, Catalytic properties of the mitochondrial NADH-ubiquinone oxidoreductase (2008)](https://doi.org/10.1016/j.bbagen.2008.03.001)
[Johri A, Beal MF, Mitochondrial dysfunction in neurodegenerative diseases (2012)](https://doi.org/10.1177/1759091411423216)
[Pickrell AM, Youle RJ, The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease (2015)](https://doi.org/10.1016/j.neuron.2015.06.007)
[Exner N, Lutz AK, Haass C, Winklhofer KF, Mitochondrial dysfunction in Parkinson's disease (2012)](https://doi.org/10.1177/1759091411421436)
[Beal MF, Mitochondria and neurodegeneration (2005)](https://doi.org/10.1016/j.neuron.2005.09.012)
[Lautrup S, Sinclair DA, Mattson MP, Fang EF, NAD+ in brain aging and neurodegenerative disorders (2019)](https://doi.org/10.1016/j.cmet.2019.06.001)